- Swiss drugmaker Novartis (NYSE:NVS) acquires privately held Vedere Bio, a company focused on advancing photoreceptor-protein-based optogenetic therapies delivered to retina to restore functional vision.
- Shareholders in Vedere Bio received $150M upfront and will be eligible for up to $130M in milestone payments, for a total of $280M.
- "Our proprietary intravitreal capsids enable not only Vedere Bio's optogenetics products but also other ocular gene therapies," said Cyrus Mozayeni, M.D., CEO, President of Vedere Bio.
- https://seekingalpha.com/news/3627953-novartis-buys-vedere-bio-for-280m
Thursday, October 29, 2020
Novartis buys Vedere Bio for $280M
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.